- Home
- PEGA vs BBIO Comparison
PEGA vs BBIO Comparison
Compare PEGA & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEGA
- BBIO
- Stock Information
- Founded
- PEGA 1983
- BBIO 2015
- Country
- PEGA United States
- BBIO United States
- Employees
- PEGA N/A
- BBIO N/A
- Industry
- PEGA EDP Services
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PEGA Technology
- BBIO Health Care
- Exchange
- PEGA Nasdaq
- BBIO Nasdaq
- Market Cap
- PEGA 6.3B
- BBIO 6.7B
- IPO Year
- PEGA 1996
- BBIO 2019
- Fundamental
- Price
- PEGA $69.52
- BBIO $34.57
- Analyst Decision
- PEGA Buy
- BBIO Strong Buy
- Analyst Count
- PEGA 12
- BBIO 12
- Target Price
- PEGA $100.17
- BBIO $52.64
- AVG Volume (30 Days)
- PEGA 827.7K
- BBIO 2.7M
- Earning Date
- PEGA 04-23-2025
- BBIO 05-01-2025
- Dividend Yield
- PEGA 0.17%
- BBIO N/A
- EPS Growth
- PEGA 50.76
- BBIO N/A
- EPS
- PEGA 1.11
- BBIO N/A
- Revenue
- PEGA $1,497,180,000.00
- BBIO $221,902,000.00
- Revenue This Year
- PEGA $8.60
- BBIO $12.42
- Revenue Next Year
- PEGA $6.89
- BBIO $123.19
- P/E Ratio
- PEGA $62.66
- BBIO N/A
- Revenue Growth
- PEGA 4.51
- BBIO 2285.27
- 52 Week Low
- PEGA $54.55
- BBIO $21.62
- 52 Week High
- PEGA $113.67
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- PEGA 35.09
- BBIO 51.35
- Support Level
- PEGA $70.44
- BBIO $35.77
- Resistance Level
- PEGA $76.68
- BBIO $37.06
- Average True Range (ATR)
- PEGA 2.30
- BBIO 1.40
- MACD
- PEGA 0.62
- BBIO 0.18
- Stochastic Oscillator
- PEGA 25.80
- BBIO 47.67
About PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.